YLT192, a Novel, Orally Active Bioavailable Inhibitor of VEGFR2 Signaling with Potent Antiangiogenic Activity and Antitumor Efficacy in Preclinical Models

Antagonizing vascular endothelial growth factor receptor 2 (VEGFR2) to block angiogenesis has been applied toward cancer therapy for its role in promoting cancer growth and metastasis. However, most these clinical anticancer drugs have unexpected side effects. Development of novel VEGFR2 inhibitors...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Xia, Yong, Song, Xuejiao, Li, Deliang, Ye, Tinghong, Xu, Youzhi, Lin, Hongjun, Meng, Nana, Li, Guobo, Deng, Senyi, Zhang, Shuang, Liu, Li, Zhu, Yongxia, Zeng, Jun, Lei, Qian, Pan, Youli, Wei, Yuquan, Zhao, Yinglan, Yu, Luoting
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Nature Publishing Group 2014
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4129416/
https://ncbi.nlm.nih.gov/pubmed/25112436
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/srep06031
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak